


GOALS

- Develop & validate a LC-MS/MS procedure for the qualitative screening of >100 veterinary drugs in milk-, meat- and seafood-based products. Method to be adapted for heavy routine environments requiring short turn-around-times.
- Targets: 108 drugs belonging to 23 Families, namely Amphenicols (3), Avermectins (6), Benzimidazoles (14), Coccidiostats-ionophores (5) and non ionophores (6), Diaminopyrimidines (2), Lincosamides (2), Macrolides (8), Nonsteroidal anti-inflammatory drugs (NSAID) (5), Quinolones (18), Rifamycins (2), Salicylanilides (4), Sulfonamides (22), Tranquilizers (2) and others (9).
- For all analyte/matrix combinations, ensure that Screening Target Concentrations (STC) are at or below Maximum Levels stipulated in EU 37/2010 and CODEX regulations [1-2].

EXTRACTION PROCEDURE

Modified QuEChERS protocol comprising a dedicated clean up for AVERMECTINS. Large variations in matrix effects require each sample to be extracted twice: one as such and the other spiked at the Screening Target Concentration (STC).



- Acidified mixture of water/acetonitrile is required to efficiently promote protein precipitation.
- Na₂SO₄ (instead of MgSO₄) is employed as initial partitioning salt and in the d-SPE salt mixture to avoid chelation of Quinolones (MULTI-FAMILY method).
- Citrate salts are **mandatory** for an efficient buffering of extracts due to the broad range of compound pKas.
- Each resulting extract is divided in two portions which subsequently undergo different d-SPE cleanup to deal with AVERMECTINS **particular behavior**.
- Reconstitution of AVERMECTINS extract in high percentage organic solvent to avoid **adsorption** onto LC vials

INSTRUMENTAL PARAMETERS (Agilent 1290 Infinity & Sciex Qtrap 5500)



- LC column: Waters Acquity BEH C18, 2.1 x 100 mm, 1.8 μm
- Temperature: 40 °C
- Flow rate: 400 μL/min
- Injection volume: 10 μL
- Mobile phase A: 0.1 % Formic acid / 0.5 mM Ammonium formate in water
- Mobile phase B: 0.1 % Formic acid / 0.5 mM Ammonium formate in methanol
- Gradient flow
- Two LC runs: 16 min (MULTI-FAMILY) and 10 min (AVERMECTINS)

PARAMETERS	MULTI-FAMILY	AVERMECTIN
Ionisation type	Electrospray	Electrospray
Polarity	Positive / Negative switching	Positive
Ion spray voltage (IS)	5000 / -4500 V	5500 V
Temperature (TEM)	550 °C	350 °C*
Scheduled MRM	Enabled as Basic	Not used


* Lower MS source temperature required to deal with Avermectins thermolability



VALIDATION according to EU CRL 2010/01/20 [3]

- Aim** is to check if samples are below or potentially above the Screening Target Concentration (STC).
- Results** are either \leq STC (expressed in μg/kg) or **Suspect** (i.e. potentially > STC) to be further confirmed by a confirmatory quantitative analysis.
- Response measured** as a relative comparison between Peak Area in Unspiked Sample (A_{US}) vs. Peak Area in the related Spiked Sample (A_S).


Validation scheme:



*Cut-off determination: The cut-off value is the value above which a sample is classified as suspect

- Response in blank sample = $(\text{Peak area in unspiked sample} / \text{Peak area in 1 STC}) * 100$
- Response in spiked sample = $(\text{Peak area in 1 STC sample} / \text{Peak area in 2 STC sample}) * 100$

→ cut-off level must be set to ensure that highest response in blank samples is below lowest response in spiked samples (see example for Albendazole below)



RESULTS

Family	Nb of compounds	STC (μg/kg)	Cut-off (%)	FP rate (%)	FN rate (%)
Amphenicols	3	0.3 to 10	20%	100 % PASSED All FP < 3 %	98 % PASSED ALL FN < 4 % Not passed for* Clorsulon Tulathromycin A
NSAID	5	5			
Avermectins	6	10			
Benzimidazoles	14	2 to 5			
Coccidiostats / ionophores	5	15			
Coccidiostats / non ionophores	6	15			
Diaminopyrimidines	2	15			
Lincosamides	2	15			
Macrolides	8	15			
Quinolones	18	10			
Rifamycins	2	15			
Salicylanilides	4	10 to 15			
Sulfonamides	22	5 to 10			
Tranquilizers	2	15			
Others	9	5 to 15			

* Clorsulon and Tulathromycin A gave FN > 5% due to the absence of SRM2 signal

CONCLUSIONS

- Straightforward workflow, suitable for routine environment, applicable to all milk-, meat- and seafood-based products surveyed**
- 106 out of 108 compounds fulfill the analytical requirement with both FP/FN rates < 5%**

* Contact point: Aurelien.Desmarchelier@rdls.nestle.com

[1] Commission Regulation (EU) No 37/2010 on Pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origins

[2] Codex Alimentarius Commission Maximum Residue Limits for Veterinary Drugs in Foods

[3] EU Community Reference Laboratories (CRL) Guidelines for the validation of screening methods for residues of veterinary medicines; 2010-01-20